Here's Why You Should Invest in Insulet (PODD) Stock for Now

Here's Why You Should Invest in Insulet (PODD) Stock for Now. Zacks Equity Research ... stock has gained 38.8% compared with a 9% rise of the industry and a 10.8% rise of the S&P 500 composite ...

CouponFollow Extension

8%
OFF

Here's Why You Should Invest In Insulet (PODD) Stock For Now

3 weeks from now

Here's Why You Should Invest in Insulet (PODD) Stock for Now. Zacks Equity Research ... stock has gained 38.8% compared with a 9% rise of the industry and a 10.8% rise of the S&P 500 composite ...

yahoo.com

5%
OFF

Here's Why You Should Invest In Insulet (PODD) Stock For Now

3 weeks from now

Oct 16, 2023 · You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. DaVita has gained 25.5% against the industry’s 8.9% decline in the past year. Cardinal Health …

nasdaq.com

9%
OFF

Here's Why You Should Invest In Insulet (PODD) Stock For Now

3 weeks from now

Oct 16, 2023 · Here's Why You Should Invest in Insulet (PODD) Stock for Now ... stock has declined 40.9% compared with the 20.6% fall of the industry and a 18.1% rise of the S&P 500 …

yahoo.com

46%
OFF

Here's Why You Should Retain Insulet (PODD) Stock For Now

3 weeks from now

Feb 16, 2024 · You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Stryker, carrying a Zacks Rank #2 at present, has an earnings yield of 3.46% against the …

nasdaq.com

$20.12
OFF

Here's Why You Should Retain Insulet (PODD) Stock For Now

3 weeks from now

Jun 21, 2023 · The developer, manufacturer and distributor of insulin delivery systems has a market capitalization of $20.12 billion. Insulet projects a long-term estimated earnings growth …

nasdaq.com

$19
OFF

Insulet's SWOT Analysis: Tubeless Pump Maker's Stock

3 weeks from now

Dec 13, 2024 · Insulet (NASDAQ: PODD) Corporation (NASDAQ:PODD), a leader in tubeless insulin pump technology with a market capitalization of $19 billion, has been making significant …

investing.com

$19.52
OFF

Insulet (NASDAQ:PODD) Hits New 1-Year High - Here's What …

3 weeks from now

5 days ago · Check Out Our Latest Research Report on PODD Insulet Price Performance. 5 top healthcare stocks for earnings growth in 2024; The firm has a market cap of $19.52 billion, a …

marketbeat.com

$282.87
OFF

Insulet Stock Soars To 52-week High, Reaches $282.87 - Investing.com

3 weeks from now

3 days ago · Insulet (NASDAQ: PODD) Corporation's stock has reached a new 52-week high, with shares climbing to $282.87. This milestone reflects a significant uptrend for the medical …

investing.com

37%
OFF

Here's Why You Should Buy Insulet (PODD) Stock Right Now

3 weeks from now

Mar 18, 2024 · You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Stryker, carrying a Zacks Rank #2 at present, has an earnings yield of 3.37% compared to the …

zacks.com

$282.87
OFF

Insulet Stock Soars To 52-week High, Reaches $282.87

3 weeks from now

4 days ago · Insulet (NASDAQ: PODD) Corporation's stock has reached a new 52-week high, with shares climbing to $282.87. This milestone reflects a significant uptrend for the medical …

investing.com

$27.37
OFF

Insulet Corp Executive Exercises Options, Sells Shares

3 weeks from now

May 29, 2024 · The transaction involved the acquisition of 18,267 shares of Insulet Corp's common stock through the exercise of options, with prices ranging from $27.37 to $40.6, …

investing.com

FAQs about Here's Why You Should Invest in Insulet (PODD) Stock for Now Coupon?

Is Insulet Corporation (Podd) a good stock to buy?

Insulet Corporation PODD is well-poised to gain in the coming quarters, backed by the strength of its revolutionary Omnipod 5 Automated Insulin Delivery (“AID”) system. The continued market expansion of Omnipod DASH is also highly encouraging. Strong solvency is an added upside. ...

Should you buy Podd Insulet Corporation (PDD)?

PODD Insulet Corporation’s PODD rapid commercial expansion and increasing market access capabilities for its Omnipod platform are poised to help it grow in the upcoming quarters. The rising adoption of Omnipod 5 also presents a promising growth opportunity. Besides, a sound financial position bodes well for the stock. ...

Is Podd a good stock to buy?

It is worn on the body for approximately three days at a time and allows virtually pain-free automated cannula insertion and blood glucose meter integration. PODD is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. Additionally, the company could be a top pick for growth investors. ...

Should you buy Omnipod 5 (Podd) stock?

Omnipod 5 remains a disruptive force in the diabetes technology market as the only FDA-approved, fully disposable, pod-based AID system. Investors remain confident in the Insulet (PODD) stock due to the huge success of Omnipod 5. ...

Is Insulet Corporation gaining from the Omnipod 5 development roadmap?

Insulet Corporation PODD is gaining from the significant progress with respect to its development roadmap of the Omnipod 5 system. The international rollout of the device continues successfully. Meanwhile, inflationary pressures will likely sustain throughout the year, affecting the company’s gross margins and net income. ...

Is Podd a good pick for Growth Investors?

Additionally, the company could be a top pick for growth investors. PODD has a Growth Style Score of B, forecasting year-over-year earnings growth of 17.1% for the current fiscal year. For fiscal 2024, five analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.22 to $3.22 per share. ...